(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 14.93% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 2.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 130.39%.
Exagen's revenue in 2025 is $58,862,000.On average, 4 Wall Street analysts forecast XGN's revenue for 2025 to be $1,488,546,314, with the lowest XGN revenue forecast at $1,474,243,947, and the highest XGN revenue forecast at $1,507,249,409.
In 2026, XGN is forecast to generate $1,711,883,270 in revenue, with the lowest revenue forecast at $1,694,280,357 and the highest revenue forecast at $1,751,489,824.